Multi-analyte profiling and pathway analysis of plasma for proteins associated with cancer-related fatigue syndrome in disease-free breast cancer patients after primary treatment. by Minton, O et al.
1 
 
Multi-analyte profiling and pathway analysis of plasma for proteins associated with cancer 
related fatigue syndrome in disease-free breast cancer patients after primary treatment 
Minton O* 
Coulton GR PhD St Georges University of London  
Stone P MA MD FRCP St Georges University of London  
*Corresponding author 
 
Dr Ollie Minton PhD FRCP 
Consultant and honorary senior lecturer in palliative medicine St George’s University of 
London 
Division of population health sciences and education  
6th floor Hunter wing  
St Georges University of London  
Cranmer Terrace  
London SW17 ORE 
Phone: 02087252620 
Email: ominton@sgul.ac.uk 
 
Running title: cytokines linked to fatigue  
Key words: 
Breast neoplasm 
Survivors 
Cytokines 
Fatigue  
This work is funded by Cancer research UK grant number C11075/A10090.  
The authors declare no conflict of interest. 
 
2 
 
Abstract 
Context A significant number of women treated for breast cancer develop long term fatigue 
afterwards. Previous research has suggested that fatigue may be due to a prolonged 
inflammatory response. However there are conflicting results and the exact nature of the 
disturbance remains unclear. 
 
Objectives We wanted to identify any inflammatory markers associated with fatigue  
 
Methods We recruited women from a breast cancer follow up clinic and categorised them on 
the basis of a diagnostic interview as to whether they met the criteria for cancer related 
fatigue syndrome (cases) or not (controls).  We took plasma samples from each participant 
to analyse subsequently using a panel of 88 biological markers. 
 
Results 90 samples were analysed in total (45 cases and 45 controls). A factorial Analysis 
of variance (using age as a fixed factor) demonstrated a number of differences in 
inflammatory cytokines. There were 28 significantly different analytes in total. Granulocyte 
colony stimulating factor (GCSF) was the most significantly different analyte (p<0.001).  
Many of the significant analytes were chemokine ligands found to be linked through an 
inflammatory pathway promoting T cell and granulocyte production and activation.  
 
Conclusions Our results add further weight to the hypothesis that cancer related fatigue 
syndrome is associated with an increased pro-inflammatory immune response. Our findings 
indicate that these cytokine changes could underpin the subjective symptoms such as 
perceived muscle weakness and concentration difficulties experienced by women who feel 
fatigued after treatment.
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Introduction: 
The majority of women treated for breast cancer can expect to survive for the long term[1]. 
This means that many women are living with persistent side effects of treatment including 
fatigue[2]. The prevalence of post-treatment fatigue can be as high as 30% at up to two 
years following the completion of therapy[3]. This does, however, vary with how fatigue is 
measured[4]. One of the more robust methods to categorise significant fatigue is to use a 
case definition of cancer related fatigue syndrome . This is can be done by using a 
diagnostic interview[5] and based on similar criteria used for diagnosing chronic fatigue 
syndrome[6].  
Cancer related fatigue syndrome is a clinical diagnosis which encompasses subjective 
aspects of fatigue. However the underlying biological pathogenesis is unclear and no 
objective testing of cancer related fatigue syndrome currently exists[7]. Most research has 
examined immunological disturbances and cytokine levels in relation to fatigue after 
completion of treatment. Fatigue levels with concurrent cytokine measurement have only 
been examined prospectively during radiotherapy for breast cancer [8 9]. Indirect evidence 
supporting an immunological mechanism for fatigue in chemotherapy comes from a small 
pilot trial of a tumour necrosis factor blocking drug –etanercept [10]. This demonstrated that 
etanercept reduced fatigue and thus allowed for higher doses of docetaxel chemotherapy to 
be used. The authors of a meta-analysis summarised the research investigating the 
relationship between fatigue and inflammatory markers[11] in relation to all tumour types 
both during after completion of systemic treatment. They found an association between 
fatigue and a number of pro-inflammatory cytokines with the best evidence being for a 
relationship between fatigue and interleukin 6, interleukin 1a and neopterin (secreted by 
activated macrophages). The authors of the review cited the wide range of outcome 
measures and experimental variation in different studies as factors which may explain the 
lack of consistent findings. All of these cytokines are associated with a prolonged 
inflammatory response and would fit with our current understanding of the patho-physiology 
of cancer related fatigue syndrome both occurring during and after treatment. However more 
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work is clearly needed before firm conclusions can be drawn about the relevance of any 
particular inflammatory marker. It is more than likely this inflammatory response peaks 
during treatment but persists in those patients that experience chronic fatigue [11 12].  
There is evidence from studies conducted in disease-free post-treatment breast cancer 
survivors of a prolonged inflammatory response in a subset of fatigued women[13-17]. 
These studies have used a variety of techniques to examine laboratory markers of fatigue 
including examination of lymphocyte subsets and genetic polymorphisms as well as cytokine 
measurements. However the measures this group have used have altered over time.. The 
fatigue groups were also only identified using cut-off scores on quality of life scales, rather 
than a more robust application of cancer related fatigue syndrome criteria. 
These limitations and a priori focus on a small number of pre-determined cytokines mean 
that the understanding of the pathogenesis of long term fatigue in breast cancer survivors is 
still limited. The aims of our study were to categorise breast cancer survivors into those 
meeting the criteria for cancer related fatigue syndrome and those who did not in order to 
examine differences in candidate biomarkers (including but not limited to the inflammatory 
cytokines previously identified). We also wanted to map differences onto known biological 
pathways in order to develop an explanatory model.  
 
 
Materials and methods 
 
Breast cancer survivors were recruited at St George’s Healthcare NHS Trust. Recruitment 
was from January 2009 to May 2011. Approval was obtained from Wandsworth Ethics 
Committee prior to data collection (ref 08/H0803/182). 
All patients who were clinically and radiologically disease-free between three months and 
two years after the end of their primary treatment (of any modality) were invited to 
participate.  
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Those patients with significant cognitive impairment, psychiatric history or medical co-
morbidities on initial screening were excluded from the study (12 women in total). 
Participants underwent the following: 
 
Diagnostic interview for cancer related fatigue  
This interview determines whether the participant meets the four criteria for a diagnosis of 
cancer related fatigue syndrome [18]. Criterion A; The presence of two weeks of significant 
fatigue in the preceding month and the presence of at least five out of nine other fatigue-
related symptoms. These include sleep and cognitive disturbance and functional impact of 
fatigue. Criterion B; The fatigue has a significant effect on work or self-care. Criterion C; The 
fatigue symptoms are a consequence of cancer or cancer therapy. Criterion D; The 
symptoms are not primarily a consequence of a co-morbid psychiatric disorder. The final 
criterion can be assessed clinically but the most robust method is to use a contemporaneous 
psychiatric interview. Participants with a significant current psychiatric history which was felt 
to be contributing to fatigue were excluded. This was usually a con-current clinically 
significant mood disorder.  
 
Structured Clinical Interview for the Diagnostic and Statistical Manual (DSM) – IV (SCID) 
The SCID provides a method for obtaining DSM-IV diagnoses. The procedure has been 
successfully used in previous studies examining CRF syndrome [19 20] and by our group 
[3]. All interviews were conducted by the same person (OM). This procedure allowed for the 
classification of women into cases of cancer related fatigue syndrome or controls (those who 
did not meet the criteria). The presence of a diagnostic mood disorder (such as major 
depression) meant we excluded those women from further analysis because of the potential 
for overlap in symptoms [21]. 
Group Analysis  
The between group analysis was conducted on those meeting the criteria and an equal 
number of the control group (those patients  with the lowest scores on the functional 
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assessment of cancer therapy fatigue subscale (FACT F[22]) in order to maximise the 
differences between groups). The FACT F is a thirteen item fatigue questionnaire widely 
used in the assessment of cancer fatigue. [23].. 
 
Analysis of blood samples 
A blood sample was obtained using Becton Dickinson (New Jersey USA)BD P100 proteomic 
vacutainer® kits. Blood was centrifuged at 2500g for fifteen minutes as per manufacturer’s 
instructions. Blood was not taken at a specific time of the day but was taken 
contemporaneously with clinical data. Plasma was then aliquoted into 0.5ml micro-centrifuge 
containers and stored at -80 degree Celsius in a locked freezer until analysis at the end of 
the study. Single 100 microlitre aliquots were transported frozen on dry ice for analysis by 
Rules Based Medicine (RBM - Austin Texas USA). RBM (www.rulesbasedmedicine.com) is 
a commercial company which provides multiple immuno-assay testing through a designated 
panel. We used HumanMap® Antigen v1.6. This is a panel of 88 potential biomarkers which 
includes but is not restricted to interleukins, cancer antigens and other cytokines (see table 
1). The panel has been generated by the company as is fixed in its makeup. 
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Table 1 List of 88 analytes from Rules Based Medicine  
 
1. Adiponectin  2. Alpha-1-Antitrypsin  
3. Alpha-2-Macroglobulin  4. Alpha-Fetoprotein  
5. Apolipoprotein A-I  6. Apolipoprotein C-III  
7. Apolipoprotein H  8. Apolipoprotein(a)  
9. Beta-2-Microglobulin  10. Brain-Derived Neurotrophic Factor  
11. Calcitonin  12. Cancer Antigen 125  
13. Cancer Antigen 19-9  14. Carcinoembryonic Antigen  
15. CD 40 antigen  16. CD40 Ligand  
17. Complement C3  18. C-Reactive Protein  
19. Creatine Kinase-MB  20. Endothelin-1  
21. EN-RAGE  22. Eotaxin-1  
23. Epidermal Growth Factor  24. Epithelial-Derived Neutrophil-Activating Protein 78  
25. Erythropoietin  26. Factor VII  
27. Fatty Acid-Binding Protein, heart  28. Ferritin  
29. Fibrinogen  30. Fibroblast Growth Factor basic  
31. Granulocyte Colony-Stimulating Factor  32. Granulocyte-Macrophage Colony-Stimulating 
Factor  
33. Growth Hormone  34. Haptoglobin  
35. Immunoglobulin A  36. Immunoglobulin E  
37. Immunoglobulin M  38. Insulin  
39. Insulin-like Growth Factor I  40. Intercellular Adhesion Molecule 1  
41. Interferon gamma  42. Interleukin-1 alpha  
43. Interleukin-1 beta  44. Interleukin-1 receptor antagonist  
45. Interleukin-10  46. Interleukin-12 Subunit p40  
47. Interleukin-12 Subunit p70  48. Interleukin-13  
49. Interleukin-15  50. Interleukin-16  
51. Interleukin-2  52. Interleukin-3  
53. Interleukin-4  54. Interleukin-5  
55. Interleukin-6  56. Interleukin-7  
57. Interleukin-8  58. Leptin  
59. Lymphotactin  60. Macrophage Inflammatory Protein-1 alpha  
61. Macrophage Inflammatory Protein-1 beta  62. Macrophage-Derived Chemokine  
63. Matrix Metalloproteinase-2  64. Matrix Metalloproteinase-3  
65. Matrix Metalloproteinase-9  66. Monocyte Chemotactic Protein 1  
67. Myeloperoxidase  68. Myoglobin  
69. Plasminogen Activator Inhibitor 1  70. Pregnancy-Associated Plasma Protein A  
71. Prostate-Specific Antigen, Free  72. Prostatic Acid Phosphatase  
73. Serum Amyloid P-Component  74. Serum Glutamic Oxaloacetic Transaminase  
75. Sex Hormone-Binding Globulin  76. Stem Cell Factor  
77. T-Cell-Specific Protein RANTES  78. Thrombopoietin  
79. Thyroid-Stimulating Hormone  80. Thyroxine-Binding Globulin  
81. Tissue Factor  82. Tissue Inhibitor of Metalloproteinases 1  
83. Tumor Necrosis Factor alpha  84. Tumor Necrosis Factor beta  
85. Tumor necrosis factor receptor 2  86. Vascular Cell Adhesion Molecule-1  
87. Vascular Endothelial Growth Factor  88. von Willebrand Factor  
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Pathway Mapping 
The data obtained from this panel was then linked by existing biological relationships (such 
as binding or regulation) using Pathway StudioTM software (Ariadne Genomics, 
MarylandUSA)..This is a software program that allows biological systems mapping and 
concurrent database searching to provide information on protein interactions. The software 
allowed interactions between the significant RBM anlaytes to be identified. This was done in 
two ways – 1) By using the software to find known links between identified proteins (from the 
RBM panel) and 2) Using a probability threshold (P<0.05) to find potential interactions 
between the RBM analytes and other proteins that enrich the pathway. This was based on a 
probability assessment made from electronic searching of the published literature extracted 
by Medscan software® part of the Pathway StudioTM software. This gave an indication of the 
highest probability linkages between the RBM analytes and other directly linked (but 
unmeasured) proteins. This was done in order to generate a system-level hypothesis for the 
mechanism of cancer related fatigue syndrome in this group and to place the statistical 
analysis within a biological network. The principle is to visually represent previously identified 
links between proteins. The more extensive the links, the more biologically active and 
potentially relevant to the pathogenesis of cancer fatigue it is. This biological linkage in 
analytes does not rely on the limitations of fatigue research discussed  [11] 
Statistical considerations 
The RBM analyses have an upper and lower detectable limit for all analytes and any value 
below this level was reported as “missing”. Analytes for which more than 50% of data were 
missing were excluded from the analysis (12 analytes). 
The measured analytes vary widely in their level of concentration even in normal plasma 
(from milligrams/ml to picograms/ml – a 109 fold difference between highest and lowest 
concentrations). Raw data from RBM was therefore initially transformed to normalise and 
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impute missing data. For certain analytes there was a small percentage of missing values 
(i.e. below the lowest detectable range). This was no more than twenty per cent of values in 
less than ten per cent of analytes. In order to be able to compare these analytes equally data 
were imputed. This was calculated by dividing the lowest measurable value overall for that 
analyte by two. This procedure was undertaken to ensure that there were no missing data 
and so all cases could be included in a multi-variate analysis.   
Data was normalised to allow for direct comparison across all analytes. This was calculated 
by taking the original value minus the minimum value for each analyte divided by the range 
of analyte values. This transformation means that all analytes are scored between 0 and 1. 
Where 0 is the lowest possible value and 1 is the highest value for each analyte. This allows 
for direct comparison of the greatest differences between groups across all analytes. There 
were no major outliers and all samples were included in the analysis. 
The role of age and other treatment and staging variables was assessed using an analysis 
of covariance (ANCOVA). This was undertaken to determine if any of these confounding 
variables contributed to the between group differences in cytokine levels. However this was 
an exploratory study and no correction was made for multiple analyses and the results have 
been interpreted in this context. 
 
Results 
 
The detailed clinical characteristics of this group have been reported in a separate paper 
[24]. In total 114 women were recruited the study. This gives a prevalence of 39% of Cancer 
related fatigue syndrome. This figure is in keeping with the wider literature [2]. There were no 
statistically significant differences between groups in mean age and time since completion of 
treatment. There is also no statistically significant difference in the frequency of lymph node 
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positivity (as a major staging variable) or treatment modalities employed (such as 
chemotherapy).Concurrent hormone usage was also not significantly different between the 
two groups. 
  Samples from 90 women were analysed (45 cases and 45 controls). There were no 
differences in routine laboratory measures (notably on full blood count or thyroid function) 
between groups. There was no difference on pathological staging or treatment modality 
between group effect on an analysis of co-variance. This demonstrated that these variables 
did not have a statistically significant impact on cytokine levels between groups. 
 However age was found to be a significant co-variate. Therefore a factorial ANOVA was 
conducted with the samples being divided into three different age groups (30-49;50-69; 70-
89). The youngest participant was 30 years old and the oldest was 89 (there was no upper 
age limit on study entry). This age group allocation meant the age group distributions were 
matched between cancer related fatigue syndrome and control groups. This meant age 
became a fixed factor in the analysis and was controlled for. 
We found twenty eight significantly different analytes between cancer related fatigue 
syndrome  and controls. The greatest statistical difference was in Granulocyte Colony 
Stimulating Factor (GCSF) concentrations (P<0.001). However a number of chemokine 
ligands related to T cell and granulocyte proliferation were also found to be significantly 
different (CD40 antigen, macrophage inflammatory protein 1(MIP1 alpha) and chemokine 
ligand 5). 
There were also a number of acute phase analytes (e.g. complement C3, apolipoprotein H 
and Aspartate transaminase) that were raised in the fatigued group. However these analytes 
did not contribute significantly to the computationally-derived networks. 
The full list of significantly different analytes is shown in Table 2. All the analytes were raised 
in the fatigued group with the exception of Interleukin 1 receptor antagonist, Interleukin 13 
and sex hormone binding globulin. 
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Table 2 Factorial ANOVA with three age groupings- Analytes tabulated in order of 
significance.  
 
Analyte Residual mean 
squares 
F ratio  P value 
Granulocyte colony 
stimulating factor 
(GCSF)- synonym 
CSF2  
0.23 8.41 <0.001 
Tissue inhibitor of 
metalloproteinases 1 
(TIMP 1) 
0.20 7.04 <0.001 
Beta 2 microglobulin 
(B2M) 
0.22 6.49 <0.001 
Myoglobin  0.14 5.98 <0.001 
Tumour necrosis factor 
beta (TNF-beta) 
0.19 4.88 0.001 
Aspartate 
transaminase (AST) 
0.05 4.01 0.003 
Brain derived 
neurotrophic factor 
(BDNF)  
0.11 3.97 0.003 
Thrombospondin 1 0.08 3.75 0.004 
Apolipoprotein H 0.11 3.67 0.005 
Vascular endothelial 
growth factor (VEGF) 
0.13 3.65 0.005 
Complement C3  0.11 3.52 0.006 
CD 40 antigen 0.12 3.47 0.007 
Interleukin 7 (IL7) 0.11 3.47 0.007 
Pregnancy associated 
plasma protein A 
(PAPPA)  
0.18 3.46 0.007 
Fatty acid binding 
protein (heart) 
0.06 3.36 0.008 
T cell specific protein 
RANTES – synonym 
CCL5 (chemokine 
ligand 5) 
0.07 3.32 0.009 
Macrophage 
inflammatory protein 1 
alpha (synonym CCL3) 
0.06 3.26 0.01 
Sex hormone binding 
globulin (SHBG) 
0.13 3.22 0.01 
Macrophage derived 
chemokine  
0.10 3.13 0.01 
Granulocyte-
macrophage colony 
stimulating factor 
(GMCSF) synonym 
CSF3 
0.07 2.90 0.02 
Interleukin 1 receptor 
antagonist (IL1RN) 
0.14 2.88 0.02 
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Fibrinogen 0.05 2.83 0.02 
Alpha 2 macroglobulin( 
A2M) 
0.09 2.77 0.02 
Stem cell factor  0.07 2.69 0.03 
Interleukin 18 (IL18) 0.08 2.55 0.03 
Interleukin 15 (IL15)  0.11 2.58 0.03 
Myeloperoxidase  0.06 2.57 0.03 
Interleukin 8 (IL8) 0.08 2.54 0.03 
Interleukin 13 (IL13)  0.07 2.33 0.04 
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Sixteen analytes linked significantly on Pathway StudioTM analysis. The remaining twelve 
significant analytes were added in to the proposed pathway but failed to demonstrate any 
linkage. The putative biological linkage and candidate relationship between these sixteen 
analytes is shown in figures 1. Figure 1 demonstrates the linkage between significantly 
different RBM analytes from table 2.   
The addition of the previously identified cytokines from the literature (Tumour necrosis factor 
alpha, Interleukin 6 and neopterin) [11] did not meet the threshold probability needed to 
expand the pathway further. It is worth noting that individually these analytes (with the 
exception of neopterin which was not included) were not significantly different between 
cancer related fatigue syndrome and controls on the RBM panel. 
 
Discussion 
This is the first study to examine the biological pathogenesis of cancer related fatigue 
syndrome using a large immunoassay panel. We found significant differences between 
cases and controls. These differences were in a number chemokine ligands and pro 
inflammatory interleukins. Our data shows that a number of analytes including GCSF, MIP1 
alpha, Interleukin 1 receptor antagonist, vascular endothelial growth factor (VEGF) and 
interleukin 18 (IL18)  are significantly different between cancer related fatigue syndrome  and 
controls. These analytes are discussed in detail as they are extensively biologically linked to 
each other and have also been previously identified as associated with cancer fatigue[11]. 
There is considerable overlap in function of a number of these chemokines (mainly secreted 
by activated granulocytes) so only this subset has been highlighted. Our more novel findings 
are discussed later. 
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Our results suggests that fatigue is linked to granulocyte activity with a T cell mediated 
response and may be due to reactivation of a latent viral infection or may reflect an auto-
immune phenomenon. There was also a significant difference in myoglobin suggesting that a 
sub-clinical myositis may have a contributory role. Increased cytokine levels were linked to 
increased vascular endothelial growth factor (VEGF) which is intriguing as VEGF can alter 
the permeability of the blood brain barrier (BBB) and may be one of the mechanisms 
whereby cytokines can cross from the peripheral circulation to the central nervous system 
and thus cause the symptoms associated with cancer related fatigue syndrome.  
There are a number of acute phase proteins that are raised in the fatigued group (AST, 
complement C3, fibrinogen and Apolipoprotein H). These analytes do not link into the 
proposed pathway but do support the hypothesis that there is an ongoing pro-inflammatory 
response linked to cancer related fatigue syndrome  [25].  
 
These findings of a mixed inflammatory response are in keeping with a number of previous 
reports.  A study by Landmark-Høyvik and colleagues[26] examined gene expression in 
fatigued breast cancer survivors and found evidence of a predominately B cell mediated 
response in contrast to our study which suggests this is predominantly T cell mediated. Their 
findings suggested an altered B cell mediated immune response across several gene sets. 
While it is difficult to compare directly transcription rates with quantifiable immunoassay of 
proteins there does seem to be significant overlap. Both studies found evidence of a 
prolonged inflammatory response in the fatigued group. 
Our findings are also in keeping with the studies by Bower and colleagues [13 14 16]. The 
authors of these papers have consistently found evidence of a pro-inflammatory response in 
breast cancer survivors with fatigue. However the exact nature has differed between studies 
because of the laboratory techniques used. The classification of the fatigued group in each 
of Bower’s studies has been based on a quality of life cut-off score rather than a case based 
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approach. The consistent findings from these studies as a whole suggest a role for 
Interleukin 6, Interleukin 1b and TNF. It is likely there are multiple pathways for such a 
common symptom especially in those who have been treated for cancer. Although in our 
study these cytokines were not significantly different.  
Our novel findings of the lower concentration cytokines such as IL 13 and 18 have not been 
previously associated with fatigue. These cytokines stimulate the production of IL 6 and 
TNF[27]. However they are also affected by other pathways including via suppression of 
cytokine signalling 1 (SOCS1) [27] and this may explain why there are no overall differences 
in TNF and IL6 in this study.  As SOCS1 is an intracellular protein a further examination of 
SOCS1 gene transcription rates would be required to confirm or refute this hypothesis. 
 Our findings are at odds with work conducted by Orre et al[28] in which the authors found 
only a significant association with C reactive protein (CRP) in their analysis of fatigue in 
breast cancer survivors. However despite the large sample size in their study the fatigue 
measurement used was not contemporaneous to the blood analysis, as it is in our study. 
The authors also comment that CRP acts as an upstream marker for lower concentration 
cytokines such as IL6. Our  group previously found a significant difference in CRP levels 
between fatigue  and controls in breast cancer survivors when it was included in routine 
laboratory testing[3]. However, in another study we failed to find an association between 
CRP and severe fatigue in a large group of mixed advanced cancer patients[29]. It is likely 
that CRP is too non-specific to be a useful marker for fatigue as it is also an acute phase 
protein. CRP was included in our initial panel but was not significantly different between 
groups, most likely for this reason. 
The link with myoglobin is intriguing as it suggests that fatigue may be associated directly 
with low grade myositis  and is in keeping with the reported positive effects of exercise on 
fatigue[30]. Increased myoglobin levels have been correlated with cancer cachexia, 
measured muscle mass and composition[31]. However this was measured in advanced 
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cancer patients with established weight loss. In breast cancer survivors any effect on the 
muscle structure is likely to be more subtle[32]. The lack of difference in creatinine kinase 
between fatigue and controls supports this. The difference in IL 18 may be due to a low 
grade auto-immune myositis which has previously been linked with cancer patients[33].  
Future exercise intervention studies should investigate its effect on serum concentrations of 
these inflammatory cytokines. However, the small observed effect of exercise interventions 
on fatigue [30] may suggest that it improves muscle function without significant impact on 
any associated inflammation.  
Our findings may also explain the reported positive effects of psycho-stimulants on 
fatigue[34]. Inflammatory cytokines can act on the BBB by local direct diffusion from 
circulating plasma or activation of cranial nerve afferents – most notably the vagus 
nerve[35]. This may be why psychostimulants have been found to be effective in this group 
as they can directly affect the BBB[36]. 
An exploratory analysis to determine the power of the analytes to act as potential candidate 
markers demonstrated that all of the analytes with a P value of 0.01 or less (eighteen 
analytes) have 80% power to distinguish the fatigued group from controls with our current 
sample size. However this subset of significant analytes is not currently sufficient to be used 
in isolation as a predictive test for cancer related fatigue syndrome as many of the analytes 
included are of uncertain biological significance in this group. 
This was an extensive immuno-assay analysis focusing on one of the most troubling 
symptoms patients experience both during and after treatment. The broad exploratory nature 
of the study has allowed us to develop hypotheses about the biological pathogenesis of 
cancer fatigue. This provides a basis to investigate further the relationship between a 
sustained inflammatory response and persistent fatigue and may provide a rationale for the 
development of more targeted therapies to prevent and treat this symptom. 
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While this is one of the largest studies of its kind, with a robust classification of fatigue cases, 
the absolute numbers are small. This study was exploratory in nature and the findings can 
therefore only be provisional. Our data was cross sectional and no pre-treatment baseline 
values were available. It is possible the observed differences were secondary to decreased 
activity rather than causative. 
The cost of performing the analysis has limited the number of samples that we were able to 
evaluate.  Dichotomising the group into cancer related fatigue syndrome and controls may 
mask small individual variations and may be why the proposed model cannot fully explain 
the full biology of cancer related fatigue syndrome. It is also likely that even if a pro-
inflammatory response is the main driver of this set of symptoms there may be other 
processes at work which our panel has been unable to measure. However the similarity of 
our findings to previous work in this area strengthens these results. Although the observed 
differences may have potentially been due to type 1 errors, this is rendered less likely by the 
linkage to a common biological pathway associated with inflammation.  
There are commercially available monoclonal antibodies that may be able to disrupt the pro-
inflammatory process and minimise the prevalence of fatigue during and after treatment. 
This could include further trials of TNF alpha blockers or other commercially available 
monoclonal antibodies. . However the efficacy, toxicity and dosing regimen of these drugs 
would need to be evaluated in a clinical trial. It is possible that some of these variables may 
find a role as surrogate markers of early response to fatigue treatment or may identify sub-
sets of patients who are particularly likely to respond to targeted therapy. This would not 
necessarily be limited to breast cancer as the mechanism is likely to overlap significantly 
across all cancer types. 
Our future work aims to correlate, in prospective studies, changes in serum cytokine levels 
and other serum proteins with the diagnostic criteria for cancer related fatigue syndrome  in 
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order to generate a model that may be used to understand the pathology and develop novel 
avenues for treatment of this debilitating condition. 
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 Legend for Figure 1  
Computationally generated (Pathway StudioTM) network of putative relationships between 
significantly different RBM analytes (derived from Table 2). This map shows previously 
published molecular relationships.  
Dotted arrows indicate regulation relationships (arrow heads indicating the direction and a 
plus sign indicating up-regulation). Solid lines indicate expression relationships (direction of 
the arrow indicating the regulator and regulated molecule, plus signs indicate increased 
expression). A flat headed line indicates reduced expression of that protein. Dark single lines 
indicate binding relationships only. 
 
KEY 
B2M- beta 2 microglobulin 
BDNF- brain derived neurotrophic factor 
CCL3- synonym for Macrophage inflammatory protein 1 alpha  
CCL5- synonym for T cell specific protein RANTES 
CSF2 – synonym for granulocyte colony stimulating factor 
CSF3 – synonym for granulocyte-macrophage colony stimulating factor 
CD40 – CD40 antigen 
Interleukin 7/13/15/18 respectively   
Il1RN- Interleukin 1 receptor antagonist  
MB – Myoglobin  
SOCS1 – suppressor of cytokine signalling 1  
TIMP1- Tissue inhibitor of metalloproteinases 1 
XCl1 synonym- Tumour necrosis factor beta 
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